Leger Damien, Bonnefoy Bénédicte, Pigearias Bernard, de La Giclais Bertrand, Chartier Antoine
Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôtel-Dieu, Centre du Sommeil et de la Vigilance, 75004 Paris, France.
50000 Saint-Lô, France.
Allergy Asthma Clin Immunol. 2017 Aug 16;13:36. doi: 10.1186/s13223-017-0208-7. eCollection 2017.
Sleep disorders are often underreported to physicians by patients with allergies. This study aimed to characterize the sleep disorders associated with respiratory allergy to house dust mites (HDM) at the time of initiation of sublingual allergen immunotherapy (SLIT) in routine clinical practice.
This prospective, cross-sectional, observational study was conducted between November 2014 and March 2015 at 189 French trial sites and included 1750 participants suffering from HDM allergy who were initiating SLIT. Participants aged less than 5 years old and those who had previously started an allergen immunotherapy (AIT) for HDM allergy were not enrolled in the study. Sleep disorders were assessed by self-administered questionnaires: the Epworth Sleepiness Scale (ESS), the Insomnia Severity Index (ISI) and a modified version of the Hotel Dieu-42 (HD-42) sleep disorder questionnaire. Logistic regression models adjusted for obesity, smoking status, asthma control and nasal obstruction were used to study the relationship between allergic rhinitis (AR) classification and sleep disorders/complaints.
Of the 1786 participants enrolled, 1750 (907 adults and 843 children) composed the analysis population. The majority of participants (73.5% of adults and 65.8% of children) reported that their sleep disorders had prompted them to consult their physician. The most commonly observed sleep complaints were poor-quality sleep (50.3% of adults and 37.3% of children), snoring (48.1 and 41.4%, respectively) and nocturnal awakening (37.6 and 28.2%, respectively). Difficulties falling asleep were reported by 27.0% of adults and 24.7% of children. Adults and children suffering from severe persistent AR experienced sleep complaints significantly more often than participants with intermittent or mild persistent AR.
This study highlights the high frequency of sleep disorders and their significant impact on patients with AR induced by HDM, in particular when AR is persistent and severe. Consequently, asking allergic patients about the quality of their sleep appears to be important, especially when the patient has persistent and severe AR.
过敏患者往往未向医生充分报告睡眠障碍情况。本研究旨在描述在常规临床实践中,舌下变应原免疫疗法(SLIT)起始时与屋尘螨(HDM)呼吸道过敏相关的睡眠障碍特征。
本前瞻性、横断面观察性研究于2014年11月至2015年3月在法国的189个试验点进行,纳入1750名开始接受SLIT治疗的HDM过敏患者。年龄小于5岁的参与者以及先前已开始针对HDM过敏进行变应原免疫疗法(AIT)的参与者未纳入本研究。通过自我填写问卷评估睡眠障碍:爱泼沃斯思睡量表(ESS)、失眠严重程度指数(ISI)以及改良版的迪厄医院 - 42(HD - 42)睡眠障碍问卷。使用针对肥胖、吸烟状况、哮喘控制情况和鼻塞进行校正的逻辑回归模型,研究变应性鼻炎(AR)分类与睡眠障碍/主诉之间的关系。
在纳入的1786名参与者中,1750名(907名成人和843名儿童)构成分析人群。大多数参与者(73.5%的成人和65.8%的儿童)报告称,他们的睡眠障碍促使他们咨询医生。最常观察到的睡眠主诉是睡眠质量差(分别为50.3%的成人和37.3%的儿童)、打鼾(分别为48.1%和41.4%)以及夜间觉醒(分别为37.6%和28.2%)。27.0%的成人和24.7%的儿童报告入睡困难。与间歇性或轻度持续性AR的参与者相比,患有重度持续性AR的成人和儿童睡眠主诉的发生率明显更高。
本研究强调了睡眠障碍的高发生率及其对HDM诱发的AR患者的重大影响,特别是当AR为持续性且严重时。因此,询问过敏患者的睡眠质量似乎很重要,尤其是当患者患有持续性且严重的AR时。